Spatiotemporal Concurrent PARP Inhibitor Sensitization Based on Radiation‐Responsive Nanovesicles for Lung Cancer Chemoradiotherapy

Abstract

AbstractThe implementation of chemoradiation combinations has gained great momentum in clinical practices. However, the full utility of this paradigm is often restricted by the discordant tempos of action of chemotherapy and radiotherapy. Here, a gold nanoparticle‐based radiation‐responsive nanovesicle system loaded with cisplatin and veliparib, denoted as CV‐Au NVs, is developed to augment the concurrent chemoradiation effect in a spatiotemporally controllable manner of drug release. Upon irradiation, the in situ generation of •OH induces the oxidation of polyphenylene sulfide from being hydrophobic to hydrophilic, resulting in the disintegration of the nanovesicles and the rapid release of the entrapped cisplatin and veliparib (the poly ADP‐ribose polymerase (PARP) inhibitor). Cisplatin‐induced DNA damage and the impairment of the DNA repair mechanism mediated by veliparib synergistically elicit potent pro‐apoptotic effects. In vivo studies suggest that one‐dose injection of the CV‐Au NVs and one‐time X‐ray irradiation paradigm effectively inhibit tumor growth in the A549 lung cancer model. This study provides new insight into designing nanomedicine platforms in chemoradiation therapy from a vantage point of synergizing both chemotherapy and radiation therapy in a spatiotemporally concurrent manner.